TCGA-OR-A5J6-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.448
- BILE_ACID_METABOLISM+0.393
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.357
- FATTY_ACID_METABOLISM+0.350
- OXIDATIVE_PHOSPHORYLATION+0.330
- XENOBIOTIC_METABOLISM+0.296
- CHOLESTEROL_HOMEOSTASIS+0.254
- PEROXISOME+0.235
- COMPLEMENT+0.229
- COAGULATION+0.209
Top 10 suppressed
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.557
- ANGIOGENESIS-0.445
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.432
- HEDGEHOG_SIGNALING-0.411
- MYC_TARGETS_V2-0.355
- WNT_BETA_CATENIN_SIGNALING-0.327
- MYC_TARGETS_V1-0.275
- APICAL_SURFACE-0.216
- MITOTIC_SPINDLE-0.193
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-67-3770-01A-01R-0946-07 | — | cohortA1 | 0.862 |
| 2 | SRR15030860 | — | — | 0.855 |
| 3 | TCGA-44-2655-01A-01R-0946-07 | — | cohortA2 | 0.845 |
| 4 | ERR2598330 | fetal | fetal | 0.840 |
| 5 | TCGA-05-5423-01A-01R-1628-07 | — | cohortA1 | 0.832 |
| 6 | TCGA-OR-A5LH-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.814 |
| 7 | SRR4195645 | — | — | 0.813 |
| 8 | SRR11296843 | — | — | 0.805 |
| 9 | SRR8613769 | — | F | 0.800 |
| 10 | TCGA-CQ-6222-01A-11R-1915-07 | — | — | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.448 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.393 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.357 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.296 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.254 | Remibrutinib | — uncovered |
| PEROXISOME | 0.235 | Idelalisib | — uncovered |
| COMPLEMENT | 0.229 | Inavolisib | — uncovered |
| COAGULATION | 0.209 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.184 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.178 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.164 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.156 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.146 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.134 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.101 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.094 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.091 | Idelalisib | — uncovered |